Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer's disease in an administrative claims database.

Nair R, Haynes VS, Siadaty M, Patel NC, Fleisher AS, Van Amerongen D, Witte MM, Downing AM, Fernandez LAH, Saundankar V, Ball DE.

BMC Geriatr. 2018 Oct 16;18(1):243. doi: 10.1186/s12877-018-0920-2.

2.

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.

Witte MM, Foster NL, Fleisher AS, Williams MM, Quaid K, Wasserman M, Hunt G, Roberts JS, Rabinovici GD, Levenson JL, Hake AM, Hunter CA, Van Campen LE, Pontecorvo MJ, Hochstetler HM, Tabas LB, Trzepacz PT.

Alzheimers Dement (Amst). 2015 Jul 26;1(3):358-67. doi: 10.1016/j.dadm.2015.06.006. eCollection 2015 Sep.

3.

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia.

Degenhardt EK, Witte MM, Case MG, Yu P, Henley DB, Hochstetler HM, D'Souza DN, Trzepacz PT.

Psychosomatics. 2016 Mar-Apr;57(2):208-16. doi: 10.1016/j.psym.2015.12.002. Epub 2015 Dec 3.

4.

Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.

Trzepacz PT, Hochstetler H, Yu P, Castelluccio P, Witte MM, Dell'Agnello G, Degenhardt EK; Alzheimer''s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2016;41(1-2):68-79. doi: 10.1159/000441351. Epub 2015 Dec 2.

PMID:
26625159
5.

Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.

Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Aug;11(8):986-93. doi: 10.1016/j.jalz.2015.03.002. Epub 2015 Apr 24.

6.

Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer's disease dementia.

Witte MM, Trzepacz P, Case M, Yu P, Hochstetler H, Quinlivan M, Sundell K, Henley D.

J Neuropsychiatry Clin Neurosci. 2014 Summer;26(3):214-20. doi: 10.1176/appi.neuropsych.12120402.

PMID:
24618911
7.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175
9.

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

Witte MM, Case MG, Schuh KJ, Ascher-Svanum H.

Curr Med Res Opin. 2012 Mar;28(3):315-23. doi: 10.1185/03007995.2012.657300. Epub 2012 Jan 31.

PMID:
22236137
10.

Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.

Trzepacz PT, Spencer TJ, Zhang S, Bangs ME, Witte MM, Desaiah D.

Curr Med Res Opin. 2011;27 Suppl 2:45-52. doi: 10.1185/03007995.2011.599372.

PMID:
21973230
11.

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Ascher-Svanum H, Zhao F, Detke HC, Nyhuis AW, Lawson AH, Stauffer VL, Montgomery W, Witte MM, McDonnell DP.

BMC Psychiatry. 2011 Sep 23;11:152. doi: 10.1186/1471-244X-11-152.

12.

Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.

Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, Zhao F, Houston JP.

J Clin Psychiatry. 2012 Mar;73(3):367-71. doi: 10.4088/JCP.10m06507. Epub 2011 Jul 12.

PMID:
21813073
13.

Long-term caloric restriction reduces metabolic rate and heart rate under cool and thermoneutral conditions in FBNF1 rats.

Knight WD, Witte MM, Parsons AD, Gierach M, Overton JM.

Mech Ageing Dev. 2011 May;132(5):220-9. doi: 10.1016/j.mad.2011.04.001. Epub 2011 Apr 12.

14.

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia.

Ascher-Svanum H, Peng X, Montgomery W, Faries DE, Lawson AH, Witte MM, Novick D, Jemiai N, Perrin E, McDonnell DP.

Eur Psychiatry. 2011 Jul-Aug;26(5):313-9. doi: 10.1016/j.eurpsy.2010.03.015. Epub 2010 Jul 10.

PMID:
20621454
15.

Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy.

Witte MM, Resuehr D, Chandler AR, Mehle AK, Overton JM.

Gen Comp Endocrinol. 2010 May 1;166(3):520-8. doi: 10.1016/j.ygcen.2010.01.006. Epub 2010 Jan 11.

16.

Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.

Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, Ball SG, Spencer TJ.

J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):176-85. doi: 10.1097/CHI.0b013e318193060e.

PMID:
20040824
17.

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.

Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP.

Pharmacogenomics J. 2009 Oct;9(5):311-8. doi: 10.1038/tpj.2009.24. Epub 2009 May 19.

PMID:
19451915
18.

AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R.

Neurology. 2007 Mar 27;68(13):1008-12.

PMID:
17389305
19.

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.

Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM.

Psychopharmacology (Berl). 2007 Jan;190(1):31-41. Epub 2006 Nov 9.

PMID:
17093981
20.

Two distinct domains within the N-terminal region of Janus kinase 1 interact with cytokine receptors.

Usacheva A, Kotenko S, Witte MM, Colamonici OR.

J Immunol. 2002 Aug 1;169(3):1302-8.

21.

P2P-R protein localizes to the nucleolus of interphase cells and the periphery of chromosomes in mitotic cells which show maximum P2P-R immunoreactivity.

Gao S, Witte MM, Scott RE.

J Cell Physiol. 2002 May;191(2):145-54. Erratum in: J Cell Physiol 2002 Sep;192(3):359-60.

PMID:
12064457
22.
25.

Homodimerization and intermolecular tyrosine phosphorylation of the Tyk-2 tyrosine kinase.

Domanski P, Yan H, Witte MM, Krolewski J, Colamonici OR.

FEBS Lett. 1995 Nov 6;374(3):317-22.

26.

Regulation of differentiation, proliferation and cancer suppressor activity.

Scott RE, Tzen CY, Witte MM, Blatti S, Wang H.

Int J Dev Biol. 1993 Mar;37(1):67-74. Review.

27.

Repression of SV40 T oncoprotein expression by DMSO.

Witte MM, Parker RF, Wang H, Scott RE.

J Cell Physiol. 1992 Apr;151(1):50-5.

PMID:
1373148
31.

Behavioural voltammetry: its application in aggression research.

Mos J, Witte MM, Olivier B, van der Poel AM, Kruk MR.

Prog Clin Biol Res. 1984;167:179-89. No abstract available.

PMID:
6542221

Supplemental Content

Loading ...
Support Center